Meropenem Stada (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final stages of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its molecular structure also provides resistance to most beta‑lactamases, preserving activity against many resistant organisms.

The dosing regimen for Meropenem Stada is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines. Dosage adjustments are especially important in patients with renal impairment. Healthcare professionals should refer to the product label and clinical protocols for specific dosing instructions.

Meropenem Stada is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus, but adequate human data are lacking. It should be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding; the decision should be based on clinical judgment and the importance of therapy for the mother.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, offering broad coverage against Gram‑negative, Gram‑positive, and anaerobic bacteria. Compared with some β‑lactam/β‑lactamase inhibitor combinations, meropenem provides greater stability against many β‑lactamases. Choice of therapy depends on local resistance patterns, infection site, patient renal function, and safety considerations.

Meropenem Stada must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period during preparation, it may be administered promptly, but prolonged exposure should be avoided to maintain potency.

Meropenem Stada is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central IV line, typically over a 15‑30‑minute infusion period. The infusion rate and total daily dose are individualized by the prescriber according to infection severity, pathogen susceptibility, and patient-specific factors such as renal function.

Serious adverse events include seizures, especially in patients with renal dysfunction or pre‑existing CNS disorders, and severe hypersensitivity reactions such as anaphylaxis. Clostridioides difficile‑associated colitis can develop after broad‑spectrum antibiotic use. Clinicians should also monitor for signs of renal impairment, thrombocytopenia, and significant liver enzyme elevations during therapy.

Meropenem Stada is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Patients with a history of severe allergic reactions to β‑lactam antibiotics should avoid its use unless no alternative therapy is available and the benefits outweigh the risks. Caution is also advised for patients with uncontrolled epilepsy or severe renal impairment.